Max Liebregts
Overview
Explore the profile of Max Liebregts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Krejci J, et al.
Arch Med Sci
. 2020 Sep;
16(5):1239-1242.
PMID: 32864015
No abstract available.
12.
Polakova E, Liebregts M, Markova N, Adla T, Kara B, Berg J, et al.
Int J Cardiol
. 2020 Jul;
319:101-105.
PMID: 32682963
Background: According to European guidelines, alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) may be less effective in patients with extensive septal scarring on cardiac magnetic resonance (CMR). This...
13.
Veselka J, Jensen M, Liebregts M, Cooper R, Januska J, Kashtanov M, et al.
Heart
. 2019 Sep;
106(6):462-466.
PMID: 31471463
Objective: The current guidelines suggest alcohol septal ablation (ASA) is less effective in hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular hypertrophy, despite acknowledging that systematic data are lacking....
14.
Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Kashtanov M, et al.
Eur Heart J
. 2019 Jun;
40(21):1681-1687.
PMID: 31152553
Aims: Based on European guidelines, alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) is indicated only in patients with interventricular septum (IVS) thickness >16 mm. The aim of this...
15.
Hoedemakers S, Vandenberk B, Liebregts M, Bringmans T, Vriesendorp P, Willems R, et al.
Acta Cardiol
. 2018 Nov;
74(3):253-261.
PMID: 30451084
Treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM) can be either conservative or invasive (alcohol septal ablation (ASA) and myectomy). As there is no clear consensus on the long-term effects...
16.
Jensen M, Faber L, Liebregts M, Januska J, Krejci J, Bartel T, et al.
Eur Heart J Qual Care Clin Outcomes
. 2018 Oct;
5(3):252-258.
PMID: 30304395
Aims: We analysed the impact of bundle branch block (BBB) and pacemaker (PM) implantation on symptoms and survival after alcohol septal ablation (ASA) in patients with hypertrophic cardiomyopathy (HCM). Methods...
17.
Veselka J, Faber L, Jensen M, Cooper R, Januska J, Krejci J, et al.
Can J Cardiol
. 2017 Dec;
34(1):16-22.
PMID: 29275877
Background: The current American College of Cardiology Foundation/American Heart Association guidelines on hypertrophic cardiomyopathy state that institutional experience is a key determinant of successful outcomes and lower complication rates of...
18.
Liebregts M, Faber L, Jensen M, Vriesendorp P, Hansen P, Seggewiss H, et al.
Europace
. 2017 Oct;
20(FI2):f198-f203.
PMID: 29016960
Aims: The HCM Risk-SCD model for prediction of sudden cardiac death (SCD) in hypertrophic cardiomyopathy recommended by the 2014 European Society of Cardiology (ESC) guidelines has not been validated after...
19.
Cooper R, Raphael C, Liebregts M, Anavekar N, Veselka J
Can J Cardiol
. 2017 Sep;
33(10):1254-1265.
PMID: 28941606
Hypertrophic cardiomyopathy is the leading cause of sudden death in young individuals and an important cause of heart failure at any age. In this review we discuss advances in investigation...
20.
Liebregts M, Vriesendorp P, Ten Berg J
J Am Coll Cardiol
. 2017 Jul;
70(4):481-488.
PMID: 28728694
Twenty years after the introduction of alcohol septal ablation (ASA) for the treatment of obstructive hypertrophic cardiomyopathy, the arrhythmogenicity of the ablation scar appears to be overemphasized. When systematically reviewing...